Concert Pharmaceuticals, Inc.
CNCE
CNCE was delisted on the 3rd of March, 2023.
123 hedge funds and large institutions have $399M invested in Concert Pharmaceuticals, Inc. in 2018 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 39 increasing their positions, 38 reducing their positions, and 21 closing their positions.
215% more call options, than puts
Call options by funds: $1.29M | Put options by funds: $410K
48% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 21
8% more funds holding
Funds holding: 114 → 123 (+9)
3% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 38
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less capital invested
Capital invested by funds: $423M → $399M (-$23.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$12.2M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$9.02M |
| 3 |
GTC
Ghost Tree Capital
New York
|
+$7.78M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.73M |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$5.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$17.3M |
| 2 |
LCM
Laurion Capital Management
New York
|
-$11.9M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
-$10.3M |
| 4 |
Millennium Management
New York
|
-$6.54M |
| 5 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$5.55M |
CNCE Hedge Fund Activity: Q1 2018 in Review
123 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q1 2018, worth a combined $399M — down 5.5% from $423M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new CNCE positions and 21 closed out — a net gain of 10 holders — while 39 added to existing stakes and 38 trimmed.
The largest buyer was Acadian Asset Management, adding an estimated $12.2M. The largest seller was Great Point Partners, exiting entirely with an estimated $17.3M sold.
- 123 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q1 2018, up from 114 in Q4 2017.
- Funds reported $399M of Concert Pharmaceuticals, Inc. stock for Q1 2018, down 5.5% quarter-over-quarter.
- 31 funds opened new Concert Pharmaceuticals, Inc. positions in Q1 2018 and 21 closed out, a net change of +10 holders.
- The largest Concert Pharmaceuticals, Inc. buyer in Q1 2018 was Acadian Asset Management, an estimated $12.2M added.
- The largest Concert Pharmaceuticals, Inc. seller in Q1 2018 was Great Point Partners, an estimated $17.3M sold.
Based on aggregated 13F filings for Q1 2018.